-
Say no to monopoly APIs!
Time of Update: 2021-11-14
On April 15, the State Municipal Supervision Bureau again notified that a large pharmaceutical company was fined 3% of its sales in 2018, totaling 764 million yuan, for its violations of the anti-monopoly law to implement a monopoly agreement.
-
Inituzumab is included in the CACA-CBCS guidelines for the first-line treatment recommendation for advanced HER2-positive breast cancer
Time of Update: 2021-11-14
As the first breast cancer anti-HER2 innovative drug independently developed by China, initumumab, a subsidiary of Sansheng Guojian, was successfully included in the recommended first-line treatment for advanced HER2-positive breast cancer .
-
National talks about drugs "should be fully equipped". The top three hospitals are no less than 30%!
Time of Update: 2021-11-14
As the new year of national talks approaches, on November 2, Zhejiang Medical Insurance Bureau issued the "Notice on Implementing the "Dual Channel" Management Mechanism for Drugs in National Medical
-
Two drugs from China Resources Double-Crane's wholly-owned subsidiaries obtained "Drug Registration Certificate"
Time of Update: 2021-11-14
On November 1, China Resources Double-Crane issued an announcement stating that its wholly-owned subsidiary, China Resources SECCO, had recently received amlodipine and atorvastatin calcium tablets and sildenafil citrate tablets from the National Food and Drug Administration.
-
Announcement of the State Food and Drug Administration on Revising the Drug Insert for Alocillin Sodium for Injection (No. 108 of 2021)
Time of Update: 2021-11-14
The marketing authorization holders of the above-mentioned drugs shall be in accordance with the "Administrative Measures for Drug Registration" and other relevant regulations, in accordance with the requirements for the revision of the drug insert for azlocillin sodium for injection (see attachment), in December 2021 Report to the provincial drug supervision and administration department for the record 2 days ago .
-
Announcement of the State Drug Administration on Issuing the "Pharmacological Vigilance Quality Management Standards" (No. 65 of 2021)
Time of Update: 2021-11-14
2. Drug marketing authorization holders and drug registration applicants shall actively prepare for the implementation of the "Pharmacological Vigilance Quality Management Regulations", establish and continuously improve the pharmacovigilance system as required, and standardize the development of pharmacovigilance activities .
-
[2021 ASH] The clinical progress of Oribatinib, a new anti-drug-resistant leukemia drug, was selected as an oral report at the ASH annual meeting for the fourth time. A total of three studies of this product were selected
Time of Update: 2021-11-14
Oribatinib (HQP1351) is the key to the treatment of tyrosine kinase inhibitor (TKI)-resistant BCR-ABL1 T315I mutant chronic myelogenous leukemia (CML-CP and CML-AP) subjects The latest results of the phase II trial 3598 Poster display Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetic (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph + ALL)
-
Eli Lilly and the U.S. government sign a $1.3 billion COVID-19 antibody supply agreement
Time of Update: 2021-11-14
In August of this year, the FDA resumed the authorization of Eli Lilly's neutralizing antibody, but only allowed to use it in states, territories and US jurisdictions where the prevalence of mutants resistant to double antibody therapy is low (less than 5%).
-
Osaikang's second biological Class 1 new drug storms the tens of billions of ophthalmology market
Time of Update: 2021-11-14
Figure 1: The latest product information declared by OsaikonSource: CDE official websiteThe announcement mentioned that ASKG712 injection can block the VEGF/VEGFR signal and effectively control the formation of new blood vessels, while also inhibiting the Ang-2 signal to improve blood vessel stability and reduce retinal inflammation, and consolidate the therapeutic effect of anti-VEGF-A .
-
once a week!
Time of Update: 2021-11-14
ArticleMedicine GuanlanRecently, the Chinese drug clinical trial registration and information disclosure platform showed that Novo Nordisk has launched a trial in China to study how NNC0174-0833 (cagrilintide) can play a role in normal weight, overweight or obese Chinese population .
-
What is Pfizer still planning to return to the world's No. 1 mRNA vaccine?
Time of Update: 2021-11-14
In the financial report, Pfizer raised its full-year sales forecast for Comirnaty's new crown vaccine by 7% to approximately US$36 billion .
Pfizer also announced the latest developments in six key R&D pipeline products including the new crown vaccine, gene therapy pipeline, PDE4 inhibitor, TL1A inhibitor, IFN-β inhibitor and oral COVID-19 drugs .
-
The National Medical Insurance Administration determines the rules for renewing contracts with volume purchases
Time of Update: 2021-11-14
All provinces, autonomous regions, municipalities directly under the Central Government, and Xinjiang Production and Construction Corps Medical Insurance Bureau: To implement the "Opinions of the General Office of the State Council on Promoting the Normalized and Institutionalized Development of Centralized and Mass Procurement of Drugs" (Guobanfa [2021] No.
-
Zhou Song, director of Sinopharm Accord, resigns
Time of Update: 2021-11-14
On November 2, Sinopharm unanimously announced that the company’s board of directors had recently received a written resignation report from director Zhou Song . Zhou Song applied to resign as a dire
-
Traditional Chinese medicine decoction pieces are frequently found to be unqualified. How should pharmaceutical companies ensure quality and safety?
Time of Update: 2021-11-14
Therefore, pharmaceutical equipment companies also need to continue to carry out technological innovation, while promoting the high-quality development of traditional Chinese medicine decoction pieces, continuously improve their own competitiveness .
-
The large-scale inter-provincial volume procurement has officially started...
Time of Update: 2021-11-14
On November 4, the Guangdong Pharmaceutical Trade Center issued the official version of the "Guangdong Union Amoxicillin and Other 45 Pharmaceutical Groups Procurement Documents", announcing the offic
-
The Chinese medicine market is showing steady growth. The industry: facing a good time that has never happened before
Time of Update: 2021-11-14
Promoted by favorable national policies and increasing demand, the market size of the Chinese medicine industry has shown a steady growth trend .
Data show that from 2016 to 2020, the compound annual growth rate of the market size of China's traditional Chinese medicine industry will reach 19.
-
Innovative Chinese medicines welcome the outbreak, and a large number of Class 1 new drugs have been applied for clinical application and marketing
Time of Update: 2021-11-14
Recently, Henan Tianfang Pharmaceutical Traditional Chinese Medicine/Shenzhen Shasong Lesheng received the CDE acceptance for the marketing application of Brainshang Lesheng Granules submitted in the new drug category 1.
-
Tianjing Biological Announces New Chief Financial Officer and Chief Strategy Officer
Time of Update: 2021-11-14
Long Jiang served as the chief financial officer or senior vice president of finance in biomedical companies such as WuXi AppTec Group, WuXi MingMa, Zhenhe Technology, and Si Microbiology, and led a number of important positions.
-
The transformation to "intelligent manufacturing" has become the general trend of the development of the pharmaceutical industry!
Time of Update: 2021-11-14
For Hongdou Group's huge investment in building a smart factory project for high-end complex anti-tumor preparations, the industry believes that this is mainly because the pharmaceutical industry is facing the challenge of large-scale production.
-
Undertake the spillover effect and continue to invest in China, Boehringer Ingelheim participated in the 4th CIIE to practice the concept of "same health"
Time of Update: 2021-11-14
Shanghai, November 2, 2021/PRNewswire/ - At the 4th CIIE, Boehringer Ingelheim, a world-renowned R&D-driven biopharmaceutical company, will bring 500+100 square meters of double booths to fully demonstrate that companies are promoting mankind And innovations in animal health .